STAT Plus: Merck scraps plans to sell a biosimilar version of Lantus as the insulin market gets crowded
REED SAXON/AP
The decision was disclosed by Samsung Bioepis, its development and commercialization partner, which noted Merck “suddenly” canceled its contract.
.png)
No hay comentarios:
Publicar un comentario